Provident Financial Services Inc(PFS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

PFS Provident Financial Services Inc

休市中 10-30 16:00:00 EDT

22.94

-0.23

-0.99%

盘后22.94

+0.000.00%

19:30 EDT

最高23.31	最低22.87	成交量95.59万
今开23.09	昨收23.17	日振幅1.90%
总市值29.96亿	流通市值28.93亿	总股本1.31亿
成交额2,196万	换手率0.76%	流通股本1.26亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"PFS","market":"US","secType":"STK","nameCN":"Provident Financial Services Inc","latestPrice":22.94,"timestamp":1793390400000,"preClose":23.17,"halted":0,"volume":955934,"hourTrading":{"tag":"盘后","latestPrice":22.94,"preClose":22.94,"latestTime":"19:30 EDT","volume":38788,"amount":889796.72,"timestamp":1793403006936,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.009926629261976712,"floatShares":126131374,"shares":130622384,"eps":2.377747,"marketStatus":"休市中","change":-0.23,"latestTime":"10-30 16:00:00 EDT","open":23.09,"high":23.31,"low":22.87,"amount":21959542.823946,"amplitude":0.01899,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.377747,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1793610000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1042693200000,"exchange":"NYSE","adjPreClose":23.17,"dividendRate":0.041835,"preHourTrading":{"tag":"盘前","latestPrice":23.2162,"preClose":23.17,"latestTime":"07:01 EDT","volume":35,"amount":818.04408,"timestamp":1793358101872,"change":0.0462,"changeRate":0.001994,"amplitude":0.05874},"postHourTrading":{"tag":"盘后","latestPrice":22.94,"preClose":22.94,"latestTime":"19:30 EDT","volume":38788,"amount":889796.72,"timestamp":1793403006936,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.2562029304017424,"impliedVol":0.1272,"impliedVolPercentile":0.2112},"requestUrl":"/m/hq/s/PFS","defaultTab":"news","newsList":[{"id":"2679657912","title":"TIL 赛道首款国产产品闯关 君赛生物诺吉仑赛注射液商业化前景几何？","url":"https://stock-news.laohu8.com/highlight/detail?id=2679657912","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679657912?lang=zh_cn&edition=full","pubTime":"2026-10-30 13:53","pubTimestamp":1793339580,"startTime":"0","endTime":"0","summary":"近日，君赛生物宣布诺吉仑赛注射液新药上市申请已获中国国家药品监督管理局受理，和信迪利单抗注射液用于既往接受过至少两种系统治疗失败的不可切除或转移性黑色素瘤患者。剔除重叠人群后，诺吉仑赛的国内年新增潜在目标患者总人数约 5400 人。结合 0.90 的临床成功概率，最终诺吉仑赛注射液黑色素瘤适应症的风险调整净现值约为 1.7 亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-10-30/doc-iniwysmx8242185.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["RCT","BK4159","ORR","BK4195","PFS","BK4211","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678914105","title":"终点达标不等于临床获益 映恩生物给ADC赛道补了一课","url":"https://stock-news.laohu8.com/highlight/detail?id=2678914105","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678914105?lang=zh_cn&edition=full","pubTime":"2026-10-27 22:00","pubTimestamp":1793109601,"startTime":"0","endTime":"0","summary":"10月26日晚间，国内ADC（抗体偶联药物）代表企业映恩生物公告有关HER2ADCDB-1303/BNT323的研发进展：该药物达到了主要终点，无进展生存期改善幅度有限，且间质性肺病发生率高于此前研究。在当前HER2低表达转移性乳腺癌的治疗格局下，该方案对相关患者的潜在获益有限。DB-1303是映恩生物与BioNTech于2023年达成合作的核心管线。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610273910520126.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610273910520126.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4552","LU0053666078.USD","BK4118","PFS","BK4585","DB","L","BK4566","LU0210528500.USD","BK4211","LU2487616109.SGD","BK4107","BK4588","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678149129","title":"九大研究贯通两大板块：艾帕洛利托沃瑞利单抗以全病程布局回应消化道肿瘤之困","url":"https://stock-news.laohu8.com/highlight/detail?id=2678149129","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678149129?lang=zh_cn&edition=full","pubTime":"2026-10-27 16:13","pubTimestamp":1793088780,"startTime":"0","endTime":"0","summary":"  编者按：2026年欧洲肿瘤内科学会(ESMO)年会于10月23日至27日在西班牙马德里召开，作为全球肿瘤领域最具影响力的学术盛会之一，ESMO始终聚焦前沿诊疗进展，引领临床实践变革方向。本届年会 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261027/c681134750.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261027/c681134750.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["PR","BAGY","CBOJ","FXN","BTCC","GBTC","CBXJ","SD","IBIT","BITX","BFAP","NETL","PXI","BTRN","YBTC","MSS","CBOO","CBXA","BCCC","CR","BPI","HPEL","BTC","BTCO","CBTY","BTCW","CBTJ","CBOA","BETH","L","MAXI","BTF","BITY","HODL","CBXY","ORR","MNRS","HPE","FBTC","BITU","CBOY","BITO","ADC","CBXO","BTCL","BFJL","BTCI","XBTY","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678192370","title":"映恩生物在研ADC药物III期数据达标 但综合获益待评估","url":"https://stock-news.laohu8.com/highlight/detail?id=2678192370","media":"中国经营报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678192370?lang=zh_cn&edition=full","pubTime":"2026-10-26 23:02","pubTimestamp":1793026954,"startTime":"0","endTime":"0","summary":"映恩生物在研ADC药物III期数据达标 但综合获益待评估","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610263908640036.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610263908640036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["PFS","BK4552","BK4211","DB","BK4566","BK4118","BK4588","BK4585","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678935411","title":"CLARITY-Gastric01 试验显示，Sone-Ve治疗二线及后线的 CLDN18.2 表达的晚期胃癌/胃食管结合部癌患者可降低死亡风险达 42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2678935411","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678935411?lang=zh_cn&edition=full","pubTime":"2026-10-26 19:06","pubTimestamp":1793012760,"startTime":"0","endTime":"0","summary":"Sone-Ve在主要终点中使三线及以后治疗患者的死亡风险降低 53%。作为首个在该治疗人群中显示生存获益的CLDN18.2靶向疗法，Sone-Ve相比于对照组，将中位生存期延长了四个多月，有望改变CLDN18.2表达患者的治疗格局。关于胃癌与胃食管结合部癌 胃癌是全球第五大常见癌症，也是第五大癌症相关死亡原因。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5080677_ZH80677_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5080677_ZH80677_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BITU","NETL","AZNH","CBTO","XBTY","CBXY","BTCW","TRAE","HODL","BITY","FBTC","BTCZ","BTCO","COAL","MNRS","GBTC","CBXA","HCC","BTF","CBTJ","DEFI","AZN","BITB","BTCL","CBOY","BETH","BPI","EAC","BRRR","SBIT","CBTY","CBXO","DFII","BAGY","IBBQ","CBOA","PFS","CBOJ","EZBC","MAXI","CBXJ","CBOO","ADC","BTC","CBTA","BTCC","BTRN","YBTC","BITO","BCCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677276908","title":"CLDN18.2靶向ADC 3期研究达到双主要终点；双靶点ADC 3期结果积极……","url":"https://stock-news.laohu8.com/highlight/detail?id=2677276908","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677276908?lang=zh_cn&edition=full","pubTime":"2026-10-24 07:35","pubTimestamp":1792798500,"startTime":"0","endTime":"0","summary":" CLDN18.2靶向ADC国际3期研究达到双主要终点，延长胃癌患者PFS和OS 武田(Takeda)和信达生物(Innovent Biologics)公布了在研CLDN18.2靶向抗体偶联药物(ADC)arcotatug tava ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261024/c681047440.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261024/c681047440.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["LU2125154935.USD","BK4532","LU0321505868.SGD","LU1670710661.SGD","LU1032466523.USD","LU2133065610.SGD","GMAB","LU0306806265.USD","LU1074936037.SGD","BK4534","ITT","LU1670711040.USD","BMY","BK4559","LU0237698245.USD","ADC","LU0225284248.USD","LU1261432733.SGD","LU1670711123.USD","LU1983299246.USD","LU0456855351.SGD","IE00BSNM7G36.USD","IHE","LU1868837136.USD","LU2596442595.SGD","LU0985481810.HKD","PFS","IE0009355771.USD","FFBC","LU0096364046.USD","LU1236620750.USD","ORR","LU0432979614.USD","LU0114720955.EUR","IE00BFTCPJ56.SGD","BK4211","LU2360032135.SGD","LU1571399168.USD","BK4585","LU1291159041.SGD","FTXH","LU0061475181.USD","BK4195","BK4231","NETL","BK4581","BK4139","LU2242646821.SGD","IE00BFXG1179.USD","LU1430594728.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107877110","title":"财报前瞻 | Provident Financial Services Inc本季度营收预计小幅增长，盈利弹性或改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1107877110","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107877110?lang=zh_cn&edition=full","pubTime":"2026-10-21 12:20","pubTimestamp":1792556427,"startTime":"0","endTime":"0","summary":"Provident Financial Services Inc将于2026年10月28日发布最新季度财报，市场预期本季度营收与利润温和增长，关注息差与资产质量变化对盈利节奏的影响。多家卖方分析认为，Provident Financial Services Inc在息差筑底与资产质量稳定的情境下，本季度EPS与EBIT存在温和上修空间，理由在于存款定价压力缓解带来的净息差弹性、费用端的纪律性管理以及信贷结构的稳健性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻 | Provident Financial Services Inc本季度营收预计小幅增长，盈利弹性或改善","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675732483","title":"劲方医药-B(02595.HK)：GFH375/VS-7375多项国内及海外临床研究取得积极进展，在多种 RAS 突变实体瘤中显示优秀疗效","url":"https://stock-news.laohu8.com/highlight/detail?id=2675732483","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675732483?lang=zh_cn&edition=full","pubTime":"2026-10-15 08:02","pubTimestamp":1792022533,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["PFS","ORR","BK4211","LU0266512127.USD","CRC","LU0456854461.SGD","BK4195","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669515363","title":"EGFR ex20ins赛道进入冲刺赛：伏美替尼申报一线适应症 国产双药同台竞技","url":"https://stock-news.laohu8.com/highlight/detail?id=2669515363","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669515363?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:19","pubTimestamp":1789975140,"startTime":"0","endTime":"0","summary":"迪哲医药的舒沃替尼、艾力斯的伏美替尼两大国产明星靶向药相继突破，国内EGFR ex20ins治疗格局有望改写。伏美替尼入局20ins一线审批国产双药同台竞技创新药赛道的竞争，本质是时间的竞争。依托WU-KONG28研究的重磅阳性结果，舒沃替尼一线EGFR ex20ins适应症上市申请于2026年5月正式获NMPA受理，并同步纳入优先审评程序。整体来看，2026年底至2027年，国内EGFR ex20ins一线赛道或将迎来双药集中获批的关键窗口期。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/observe/2026-09-21/doc-inisqkzy8948524.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4195","ORR","BK4211","IPOS","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668504920","title":"FLAURA2 III期临床研究中国人群亚组OS数据显示 泰瑞沙联合化疗一线治疗EGFR突变晚期非小细胞肺癌总生存期获益趋势与全球保持一致","url":"https://stock-news.laohu8.com/highlight/detail?id=2668504920","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668504920?lang=zh_cn&edition=full","pubTime":"2026-09-18 21:48","pubTimestamp":1789739280,"startTime":"0","endTime":"0","summary":"OS是评估肿瘤患者生存获益的\"金标准\"，此次中国人群OS数据的公布，为该方案在中国EGFR突变晚期肺癌患者中的长生存获益提供了循证依据，进一步证实奥希替尼联合化疗可成为一线标准治疗选择。晚期患者中，奥希替尼在FLAURA III期研究中作为单药疗法，以及在FLAURA2 III期研究中联合化疗，均显示出临床结局改善。作为阿斯利康持续承诺治疗早期肺癌的重要组成部分，ADAURA2 III期临床研究正在进行中，评估奥希替尼用于早期可切除EGFRm NSCLC的辅助治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5051447_ZH51447_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5051447_ZH51447_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2089984988.USD","LU2237443382.USD","BK4585","LU2462157665.USD","LU2237443622.USD","BK4211","AZNH","LU0889565916.HKD","LU0029864427.USD","LU2236285917.USD","BK4195","PFS","LU0058720904.USD","LU2237443895.HKD","LU0128525929.USD","IE00B3T34201.USD","LU1267930573.SGD","LU2456880835.USD","LU2237443978.SGD","LU2468319806.SGD","LU0432979614.USD","BK4588","BK4568","AZN","LU2237443549.SGD","LU0310800379.SGD","BK4007","LU2237443465.HKD","LU0289739699.SGD","LU0320765992.SGD","LU1829250122.USD","LU0109394709.USD","LU0708994859.HKD","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667367005","title":"优赫得一线治疗HER2突变晚期非鳞状NSCLC中位PFS达14.3个月","url":"https://stock-news.laohu8.com/highlight/detail?id=2667367005","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667367005?lang=zh_cn&edition=full","pubTime":"2026-09-16 14:05","pubTimestamp":1789538700,"startTime":"0","endTime":"0","summary":"9月14日，国际肺癌研究协会2026世界肺癌大会正在召开。会上，阿斯利康和第一三共公布了代号为DESTINY-Lung04的III期临床研究结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609163875988974.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609163875988974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4231","BK4080","BK4195","PFS","ADC","BK4211","NETL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667696659","title":"靶向HER2的ADC优赫得获新进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2667696659","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667696659?lang=zh_cn&edition=full","pubTime":"2026-09-14 16:19","pubTimestamp":1789373969,"startTime":"0","endTime":"0","summary":"靶向HER2的ADC优赫得获新进展","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609143873441151.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609143873441151.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4195","BK4211","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660810460","title":"和黄医药宣布沃瑞沙®和泰瑞沙®的联合疗法在SAFFRON全球III期研究中显示出具有统计学和临床意义的PFS和OS改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2660810460","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660810460?lang=zh_cn&edition=full","pubTime":"2026-08-17 11:12","pubTimestamp":1786936320,"startTime":"0","endTime":"0","summary":"继SACHI III期研究支持了该疗法在中国获批后，SAFFRON全球研究的结果进一步印证了其坚实的疗效，并将为泰瑞沙和沃瑞沙联合疗法的全球注册提供明确的数据支持。\" 沃瑞沙和泰瑞沙联合疗法的安全性特征与已知的各药物的安全性保持一致，且没有发现新的安全性问题。基于SACHI III期研究，沃瑞沙和泰瑞沙联合疗法已于中国获批用于治疗接受EGFR TKI治疗后疾病进展的伴有MET扩增的EGFR突变的局部晚期或转移性非小细胞肺癌患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5027243_ZH27243_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5027243_ZH27243_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["PFS","III","BK4211","BK4585","BK4531","HCM","BK1588","00013","BK4134","BK4588","BK1191","BK1587","BK4195","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119748217","title":"Provident Financial Services 及其旗下银行联手擢升 Diane Gigliotti 为高级副总裁兼首席会计官","url":"https://stock-news.laohu8.com/highlight/detail?id=1119748217","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119748217?lang=zh_cn&edition=full","pubTime":"2026-08-05 04:31","pubTimestamp":1785875489,"startTime":"0","endTime":"0","summary":"Provident Financial Services Inc（简称 Provident）及其附属机构 Provident Bank 近日宣布了一项重要人事任命。Diane Gigliotti 被正式晋升为高级副总裁，并同时担任首席会计官一职。这一举措标志着公司高层管理架构的进一步强化与完善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4211","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152712915","title":"Provident Financial Services Inc 与 Provident Bank 任命 Michael E. Regan 为董事会成员","url":"https://stock-news.laohu8.com/highlight/detail?id=1152712915","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152712915?lang=zh_cn&edition=full","pubTime":"2026-08-05 02:07","pubTimestamp":1785866829,"startTime":"0","endTime":"0","summary":"新泽西州伊瑟林，2026年8月4日——Provident Financial Services Inc及其全资子公司 Provident Bank 今日宣布，自2026年7月30日起，Michael E. Regan 已被任命为公司的董事会成员。“我们很高兴欢迎 Mike 加入 Provident Financial Services 和 Provident Bank 的董事会，”执行董事长 Christopher Martin 表示。“我深感荣幸能够加入 Provident Financial Services 和 Provident Bank 的董事会，”Regan 先生表示。Provident Financial Services Inc 是 Provident Bank 的控股公司，后者是一家自1839年以来提供“值得信赖的承诺”的社区导向型银行。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","PFS","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654395072","title":"Sonesitatug vedotin 在 CLDN18.2阳性晚期胃癌/胃食管结合部癌的二线及后线治疗中，显示出具有统计学显著性且重要临床意义的总生存期（OS）改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2654395072","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654395072?lang=zh_cn&edition=full","pubTime":"2026-07-28 12:18","pubTimestamp":1785212280,"startTime":"0","endTime":"0","summary":"关于胃癌和胃食管结合部癌 胃癌是全球第五大常见癌症，也是癌症相关死亡的第五大原因。关键次要终点为二线及后线治疗人群的总生存期。CLDN18.2是一种存在于胃黏膜上皮中的蛋白，已被验证为肿瘤治疗领域的重要治疗靶点，尤其在胃肠道肿瘤中具有重要意义。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5013526_ZH13526_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5013526_ZH13526_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BTCW","CBTY","BTRN","YBTC","CBXA","BTCO","BITX","XBTY","MNRS","CBTA","CBTO","AZN","BITY","IBBQ","AZNH","BTCI","MAXI","NETL","BTC","BFJL","BTFX","CBXO","BRRR","BCCC","BTCL","COAL","CBOJ","PFS","CBTJ","BETE","BTCZ","EZBC","CBOA","BITO","HCC","ADC","QBF","CBXJ","ARKB","EAC","BETH","CBXY","DEFI","HODL","IHC","SBIT","IBIT","BITI","BITU","FBTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183900663","title":"财报前瞻｜Provident Financial Services Inc本季度营收预计温和增长，看多观点占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1183900663","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183900663?lang=zh_cn&edition=full","pubTime":"2026-07-22 14:35","pubTimestamp":1784702150,"startTime":"0","endTime":"0","summary":"Provident Financial Services Inc将于2026年07月29日发布财报，市场聚焦息差与信用成本变动及并表后整合进展。公司未给出本季度毛利率、净利率和净利润的外部一致预测数据，故不展示。主营业务为商业与零售银行相关的“Traditional Banking and Other Financial Services”，上季度该业务收入2.27亿美元。“Traditional Banking and Other Financial Services”为营收主体，营收体量在上季度约2.27亿美元。基于近六个月内公开报道的机构与分析师研判，看多观点占据主导。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Provident Financial Services Inc本季度营收预计温和增长，看多观点占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652102268","title":"英派药业-B(07630.HK)：多项研究结果摘要获接受于2026年欧洲肿瘤内科学会大会作壁报展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2652102268","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652102268?lang=zh_cn&edition=full","pubTime":"2026-07-20 07:38","pubTimestamp":1784504331,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4211","BK4195","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128142903","title":"安东尼·佩特拉祖奥利加入Provident银行，担任存款与支付运营高级副总裁兼总监","url":"https://stock-news.laohu8.com/highlight/detail?id=1128142903","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128142903?lang=zh_cn&edition=full","pubTime":"2026-07-15 20:01","pubTimestamp":1784116897,"startTime":"0","endTime":"0","summary":"安东尼·佩特拉祖奥利已加入Provident银行，被任命为存款与支付运营高级副总裁兼总监。他将负责领导和管理银行的存款与支付相关运营业务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PFS","BK4195","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641148362","title":"康方新药取得历史性突破，为何蒸发百亿市值","url":"https://stock-news.laohu8.com/highlight/detail?id=2641148362","media":"经济观察网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2641148362?lang=zh_cn&edition=full","pubTime":"2026-06-05 19:42","pubTimestamp":1780659720,"startTime":"0","endTime":"0","summary":"6月1日，康方生物开盘后一度涨超12%，然而高开低走，此后三日连续下跌，截至6月5日收盘，康方生物总市值862亿港元，数日内市值跌去超百亿。在康方生物的叙述中，这份登陆ASCO全体会议的临床数据堪称历史性突破。无可辩驳的是，康方生物的HARMONi-6已达到全部预期终点，取得显著阳性。股价为何下跌数据公布后3日，康方生物的市值跌去超百亿港元，截至发稿，总市值已不足千亿。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-06-05/doc-iniakfhq8388122.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-06-05/doc-iniakfhq8388122.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1794554557.SGD","PFS","LU2476274308.USD","LU0348827113.USD","IE00B543WZ88.USD","BK4225","LU1961090484.USD","BK4203","06978","LU0561508036.HKD","BK4195","LU0348766576.USD","LU0348784397.USD","LU0540923850.HKD","LU2778985437.USD","LU0417516571.SGD","LU1720050803.USD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","LU0348783233.USD","HR","LU0417516902.SGD","02616","LU2399975544.HKD","BK1161","09926","LU0634319403.HKD","LU2488822045.USD","LU2476274720.SGD","LU0417516738.SGD","LU0348767384.USD","BK1574","LU0348825331.USD","BK4211","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.provident.bank","stockEarnings":[{"period":"1week","weight":-0.0129},{"period":"1month","weight":0.0357},{"period":"3month","weight":-0.0705},{"period":"6month","weight":0.025},{"period":"1year","weight":0.2407},{"period":"ytd","weight":0.1615}],"compareEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":-0.0091},{"period":"3month","weight":0.0116},{"period":"6month","weight":0.0487},{"period":"1year","weight":0.1116},{"period":"ytd","weight":0.1082}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Provident Financial Services, Inc.是一家特拉华州公司，于2003年1月15日成为Provident Bank的控股公司。该公司通过其子公司银行开展业务，该银行是一家面向社区和客户的银行，目前在新泽西州北部和中部以及宾夕法尼亚州的雄鹿县、利哈伊县和北安普敦县以及纽约州的拿骚县和皇后区经营全方位服务的分行和贷款生产办事处。该银行还通过其全资子公司Beacon Trust Company提供信托和财富管理服务，并通过其全资子公司Provident Protection Plus, Inc.提供保险服务。","yearOnYearQuotes":[{"month":1,"riseRate":0.304348,"avgChangeRate":-0.021667},{"month":2,"riseRate":0.375,"avgChangeRate":-0.016026},{"month":3,"riseRate":0.458333,"avgChangeRate":-0.003293},{"month":4,"riseRate":0.5,"avgChangeRate":0.008655},{"month":5,"riseRate":0.458333,"avgChangeRate":-0.011982},{"month":6,"riseRate":0.5,"avgChangeRate":0.002358},{"month":7,"riseRate":0.666667,"avgChangeRate":0.040582},{"month":8,"riseRate":0.5,"avgChangeRate":-0.007764},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.018969},{"month":10,"riseRate":0.666667,"avgChangeRate":0.032204},{"month":11,"riseRate":0.695652,"avgChangeRate":0.033616},{"month":12,"riseRate":0.565217,"avgChangeRate":0.013167}],"exchange":"NYSE","name":"Provident Financial Services Inc","nameEN":"Provident"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Provident Financial Services Inc(PFS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Provident Financial Services Inc(PFS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Provident Financial Services Inc,PFS,Provident Financial Services Inc股票,Provident Financial Services Inc股票老虎,Provident Financial Services Inc股票老虎国际,Provident Financial Services Inc行情,Provident Financial Services Inc股票行情,Provident Financial Services Inc股价,Provident Financial Services Inc股市,Provident Financial Services Inc股票价格,Provident Financial Services Inc股票交易,Provident Financial Services Inc股票购买,Provident Financial Services Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Provident Financial Services Inc(PFS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Provident Financial Services Inc(PFS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}